Skip to main content
Top
Published in: Tumor Biology 6/2016

01-06-2016 | Original Article

The prediction of survival of patients with gastric cancer with PD-L1 expression using contrast-enhanced ultrasonography

Authors: Lin-Ang Wang, Xi Wei, Qing Li, Lin Chen

Published in: Tumor Biology | Issue 6/2016

Login to get access

Abstract

Gastric cancer is the one of the most common cancers around the world. The prognosis of gastric cancer remains poor, due to the biological characteristics of the primary tumor as well as the recurrence after treatment. Accumulating evidence suggests the implication of programmed death ligand-1 (PD-L1) in the pathogenesis and prognosis of cancer. This study aimed to explore the CEUS as a valuable tool to improve the assessment of the therapeutic effect of the PD-L1 blocker in the treatment of gastric cancer. A total number of 105 patients with gastric cancer were enrolled in this study from June 2008 to December 2011 in our hospital. The association of PD-L1 expression level (105 cases) and CEUS parameters (100 cases) with the prognosis of gastric cancer was examined. The results showed that PD-L1-positive staining was associated with the depth of invasion, differentiation, and poor prognosis of patients with gastric cancer. The CEUS intensity (positive) exhibited poor prognosis compared to the negative counterpart. Moreover, PD-L1 and CEUS co-positivity was significantly related to a poor prognosis. The characteristic of ultrasonography images correlated with the expression of PD-L1 (r = 0.46, P = 0.0003). Collectively, the mean intensity of contrast-enhanced ultrasonography is a useful predictor in the PD-L1 expression in gastric cancer. The ultrasonography and CEUS parameter could be considered as the predictor of response to PD-L1 blocker treatment in the clinical practice.
Literature
1.
go back to reference Albiges L, Fay AP, Xie W, Krajewski K, McDermott DF, Heng DY, et al. Efficacy of targeted therapies after pd-1/pd-l1 blockade in metastatic renal cell carcinoma. Eur J Cancer (Oxford, England : 1990). 2015. Albiges L, Fay AP, Xie W, Krajewski K, McDermott DF, Heng DY, et al. Efficacy of targeted therapies after pd-1/pd-l1 blockade in metastatic renal cell carcinoma. Eur J Cancer (Oxford, England : 1990). 2015.
2.
go back to reference Hohenberger P, Gretschel S. Gastric cancer. Lancet (London, England). 2003;362:305–15.CrossRef Hohenberger P, Gretschel S. Gastric cancer. Lancet (London, England). 2003;362:305–15.CrossRef
3.
go back to reference Matsueda S, Graham DY. Immunotherapy in gastric cancer. World J Gastroenterol WJG. 2014;20:1657–66.CrossRefPubMed Matsueda S, Graham DY. Immunotherapy in gastric cancer. World J Gastroenterol WJG. 2014;20:1657–66.CrossRefPubMed
4.
go back to reference Bellmunt J, Mullane SA, Werner L, Fay AP, Callea M, Leow JJ, et al. Association of pd-l1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol Off J Eur Soc for Med Oncol ESMO. 2015;26:812–7.CrossRef Bellmunt J, Mullane SA, Werner L, Fay AP, Callea M, Leow JJ, et al. Association of pd-l1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol Off J Eur Soc for Med Oncol ESMO. 2015;26:812–7.CrossRef
5.
go back to reference Qing Y, Li Q, Ren T, Xia W, Peng Y, Liu GL, et al. Upregulation of pd-l1 and ape1 is associated with tumorigenesis and poor prognosis of gastric cancer. Drug Des Dev Ther. 2015;9:901–9.CrossRef Qing Y, Li Q, Ren T, Xia W, Peng Y, Liu GL, et al. Upregulation of pd-l1 and ape1 is associated with tumorigenesis and poor prognosis of gastric cancer. Drug Des Dev Ther. 2015;9:901–9.CrossRef
6.
go back to reference Lee MH, Choi D, Park MJ, Lee MW. Gastric cancer: imaging and staging with mdct based on the 7th ajcc guidelines. Abdom Imaging. 2012;37:531–40.CrossRefPubMed Lee MH, Choi D, Park MJ, Lee MW. Gastric cancer: imaging and staging with mdct based on the 7th ajcc guidelines. Abdom Imaging. 2012;37:531–40.CrossRefPubMed
7.
go back to reference Brenner DJ, Doll R, Goodhead DT, Hall EJ, Land CE, Little JB, et al. Cancer risks attributable to low doses of ionizing radiation: assessing what we really know. Proc Natl Acad Sci U S A. 2003;100:13761–6.CrossRefPubMedPubMedCentral Brenner DJ, Doll R, Goodhead DT, Hall EJ, Land CE, Little JB, et al. Cancer risks attributable to low doses of ionizing radiation: assessing what we really know. Proc Natl Acad Sci U S A. 2003;100:13761–6.CrossRefPubMedPubMedCentral
8.
go back to reference Piscaglia F, Corradi F, Mancini M, Giangregorio F, Tamberi S, Ugolini G, et al. Real time contrast enhanced ultrasonography in detection of liver metastases from gastrointestinal cancer. BMC Cancer. 2007;7:171.CrossRefPubMedPubMedCentral Piscaglia F, Corradi F, Mancini M, Giangregorio F, Tamberi S, Ugolini G, et al. Real time contrast enhanced ultrasonography in detection of liver metastases from gastrointestinal cancer. BMC Cancer. 2007;7:171.CrossRefPubMedPubMedCentral
10.
go back to reference Kwee RM, Kwee TC. Imaging in assessing lymph node status in gastric cancer. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2009;12:6–22. Kwee RM, Kwee TC. Imaging in assessing lymph node status in gastric cancer. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2009;12:6–22.
11.
go back to reference Wei X, Li Y, Zhang S, Xin XJ, Zhu L, Gao M. The role of contrast-enhanced ultrasound (ceus) in the early assessment of microvascularization in patients with aggressive b-cell lymphoma treated by rituximab-chop: a preliminary study. Clin Hemorheol Microcirc. 2014;58:363–76.PubMed Wei X, Li Y, Zhang S, Xin XJ, Zhu L, Gao M. The role of contrast-enhanced ultrasound (ceus) in the early assessment of microvascularization in patients with aggressive b-cell lymphoma treated by rituximab-chop: a preliminary study. Clin Hemorheol Microcirc. 2014;58:363–76.PubMed
12.
go back to reference Wei X, Li Y, Zhang S, Li X, Wang H, Yong X, et al. Evaluation of microvascularization in focal salivary gland lesions by contrast-enhanced ultrasonography (ceus) and color doppler sonography. Clin Hemorheol Microcirc. 2013;54:259–71.PubMed Wei X, Li Y, Zhang S, Li X, Wang H, Yong X, et al. Evaluation of microvascularization in focal salivary gland lesions by contrast-enhanced ultrasonography (ceus) and color doppler sonography. Clin Hemorheol Microcirc. 2013;54:259–71.PubMed
13.
go back to reference Li Y, Wei X, Zhang S, Zhang J. Prognosis of invasive breast cancer after adjuvant therapy evaluated with vegf microvessel density and microvascular imaging. Tumour Biology J Int Soc Oncodevelopmental Biol Med. 2015. Li Y, Wei X, Zhang S, Zhang J. Prognosis of invasive breast cancer after adjuvant therapy evaluated with vegf microvessel density and microvascular imaging. Tumour Biology J Int Soc Oncodevelopmental Biol Med. 2015.
14.
go back to reference Wei X, Li Y, Zhang S, Gao M. Prediction of thyroid extracapsular extension with cervical lymph node metastases (ece-ln) by ceus and braf expression in papillary thyroid carcinoma. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2014;35:8559–64.CrossRef Wei X, Li Y, Zhang S, Gao M. Prediction of thyroid extracapsular extension with cervical lymph node metastases (ece-ln) by ceus and braf expression in papillary thyroid carcinoma. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2014;35:8559–64.CrossRef
15.
go back to reference Wei X, Li Y, Zhang S, Ming G. Evaluation of thyroid cancer in chinese females with breast cancer by vascular endothelial growth factor (vegf), microvessel density, and contrast-enhanced ultrasound (ceus). Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2014;35:6521–9.CrossRef Wei X, Li Y, Zhang S, Ming G. Evaluation of thyroid cancer in chinese females with breast cancer by vascular endothelial growth factor (vegf), microvessel density, and contrast-enhanced ultrasound (ceus). Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2014;35:6521–9.CrossRef
16.
go back to reference Krupka C, Kufer P, Kischel R, Zugmaier G, Lichtenegger FS, Kohnke T, et al. Blockade of the pd-1/pd-l1 axis augments lysis of aml cells by the cd33/cd3 bite antibody construct amg 330: Reversing a t-cell-induced immune escape mechanism. Leukemia. 2015. Krupka C, Kufer P, Kischel R, Zugmaier G, Lichtenegger FS, Kohnke T, et al. Blockade of the pd-1/pd-l1 axis augments lysis of aml cells by the cd33/cd3 bite antibody construct amg 330: Reversing a t-cell-induced immune escape mechanism. Leukemia. 2015.
17.
go back to reference Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-pd-1 antibody in cancer. N Engl J Med. 2012;366:2443–54.CrossRefPubMedPubMedCentral Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-pd-1 antibody in cancer. N Engl J Med. 2012;366:2443–54.CrossRefPubMedPubMedCentral
18.
go back to reference Tang W, Chen Y, Chen S, Sun B, Gu H, Kang M. Programmed death-1 (pd-1) polymorphism is associated with gastric cardia adenocarcinoma. Int J Clin Exp Med. 2015;8:8086–93.PubMedPubMedCentral Tang W, Chen Y, Chen S, Sun B, Gu H, Kang M. Programmed death-1 (pd-1) polymorphism is associated with gastric cardia adenocarcinoma. Int J Clin Exp Med. 2015;8:8086–93.PubMedPubMedCentral
19.
go back to reference Eto S, Yoshikawa K, Nishi M, Higashijima J, Tokunaga T, Nakao T, et al. Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection. Gastric Cancer Off J Int Gastric Cancer Asso Jpn Gastric Cancer Asso. 2015. Eto S, Yoshikawa K, Nishi M, Higashijima J, Tokunaga T, Nakao T, et al. Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection. Gastric Cancer Off J Int Gastric Cancer Asso Jpn Gastric Cancer Asso. 2015.
20.
go back to reference Zheng Z, Bu Z, Liu X, Zhang L, Li Z, Wu A, et al. Level of circulating pd-l1 expression in patients with advanced gastric cancer and its clinical implications. Chin J Cancer Res Chung-kuo yen cheng yen chiu. 2014;26:104–11.PubMed Zheng Z, Bu Z, Liu X, Zhang L, Li Z, Wu A, et al. Level of circulating pd-l1 expression in patients with advanced gastric cancer and its clinical implications. Chin J Cancer Res Chung-kuo yen cheng yen chiu. 2014;26:104–11.PubMed
21.
go back to reference Suk KT, Lim DW, Kim MY, Park DH, Kim KH, Kim JM, et al. Thickening of the gastric wall on transabdominal sonography: a sign of gastric cancer. J ClinUltrasound JCU. 2008;36:462–6.CrossRefPubMed Suk KT, Lim DW, Kim MY, Park DH, Kim KH, Kim JM, et al. Thickening of the gastric wall on transabdominal sonography: a sign of gastric cancer. J ClinUltrasound JCU. 2008;36:462–6.CrossRefPubMed
22.
go back to reference Lang SA, Moser C, Gehmert S, Pfister K, Hackl C, Schnitzbauer AA, et al. Contrast-enhanced ultrasound (ceus) detects effects of vascular disrupting therapy in an experimental model of gastric cancer. Clin Hemorheol Microcirc. 2014;56:287–99.PubMed Lang SA, Moser C, Gehmert S, Pfister K, Hackl C, Schnitzbauer AA, et al. Contrast-enhanced ultrasound (ceus) detects effects of vascular disrupting therapy in an experimental model of gastric cancer. Clin Hemorheol Microcirc. 2014;56:287–99.PubMed
Metadata
Title
The prediction of survival of patients with gastric cancer with PD-L1 expression using contrast-enhanced ultrasonography
Authors
Lin-Ang Wang
Xi Wei
Qing Li
Lin Chen
Publication date
01-06-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4600-y

Other articles of this Issue 6/2016

Tumor Biology 6/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine